Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NPY1R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPY1R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPR3 Biologics Sequence Review Report 2026: Atrial natriuretic peptide receptor 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPBWR2 Biologics Sequence Review Report 2026: Neuropeptides B/W receptor type 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPBWR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPR2 Biologics Sequence Review Report 2026: Atrial natriuretic peptide receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NMBR Biologics Sequence Review Report 2026: Neuromedin-B receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NMBR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPBWR1 Biologics Sequence Review Report 2026: Neuropeptides B/W receptor type 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPBWR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCR2 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCR1 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MTNR1B Biologics Sequence Review Report 2026: Melatonin receptor type 1B Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MTNR1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MTNR1A Biologics Sequence Review Report 2026: Melatonin receptor type 1A Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MTNR1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MPL Biologics Sequence Review Report 2026: Thrombopoietin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MPL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MPIG6B Biologics Sequence Review Report 2026: Megakaryocyte and platelet inhibitory receptor G6b Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MPIG6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
209
210
211
212
213
>>
1872
>